Menu Search
Equities

Coloplast A/S

COLO B:CPH

Coloplast A/S

Actions
Health CareMedical Equipment and Services
  • Price (DKK)873.20
  • Today's Change-7.80 / -0.89%
  • Shares traded139.07k
  • 1 Year change+15.08%
  • Beta0.6093
Data delayed at least 15 minutes, as of Nov 21 2024 16:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 18-Nov-24
Select bar for recommendation details.
Recommendations18-Nov-24
Buy4
Outperform3
Hold13
Sell5
Strong Sell0

Share price forecast in DKK

The 23 analysts offering 12 month price targets for Coloplast A/S have a median target of 930.00, with a high estimate of 1,250.00 and a low estimate of 750.00. The median estimate represents a 6.50% increase from the last price of 873.20.
High43.2%1,250.00
Med6.5%930.00
Low-14.1%750.00

Dividends in DKK

In 2024, Coloplast A/S reported a dividend of 22.00 DKK, which represents a 4.76% increase over last year. The 22 analysts covering the company expect dividends of 22.01 DKK for the upcoming fiscal year, maintaining dividends from this year.
Div growth (TTM)4.76%
More ▼

Earnings history & estimates in DKK

On Nov 05, 2024, Coloplast A/S reported 4th quarter 2024 earnings of 5.84 per share. This result was in line with the consensus of the 8 analysts following the company and exceeded last year's 4th quarter results by 6.76%.
The next earnings announcement is expected on Feb 04, 2025.
Average growth rate+1.67%
Coloplast A/S reported annual 2024 earnings of 22.34 per share on Nov 05, 2024.
Average growth rate+3.45%
More ▼

Revenue history & estimates in DKK

Coloplast A/S had 4th quarter 2024 revenues of 6.95bn. This bettered the 6.89bn consensus of the 12 analysts covering the company. This was 13.89% above the prior year's 4th quarter results.
Average growth rate+2.83%
Coloplast A/S had revenues for the full year 2024 of 27.03bn. This was 10.33% above the prior year's results.
Average growth rate+9.96%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.